% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Zhang:285693,
      author       = {X.-W. Zhang$^*$ and J. Mohr and N. Halama$^*$ and R.
                      Koschny},
      title        = {{A}nalysis of an {U}nselected {P}atient {C}ohort {W}ith
                      {A}dvanced {C}olorectal {C}arcinoma from a {M}aximum {C}are
                      {C}enter.},
      journal      = {Anticancer research},
      volume       = {43},
      number       = {12},
      issn         = {0250-7005},
      address      = {Attiki},
      publisher    = {[Verlag nicht ermittelbar]},
      reportid     = {DKFZ-2023-02508},
      pages        = {5589 - 5596},
      year         = {2023},
      note         = {#EA:D240#LA:D240#},
      abstract     = {Systemic treatment for metastatic colorectal cancer (CRC)
                      includes chemotherapy in combination with a targeted
                      antibody. Novel targeted therapies and immunotherapies are
                      introduced for specific molecular subgroups. Prognostic
                      relevant determinants are still under investigation.Systemic
                      therapies of an unselected patient cohort with metastatic
                      CRC were retrospectively analyzed. Treatment outcome was
                      evaluated according to time-to-next-treatment (TTNT) and
                      frequency of conversion surgery and compared between
                      subgroups stratified by primary tumor side, molecular
                      profile, sex and age, and metastases sites.More than $50\%$
                      of patients with locally advanced or metastatic CRC
                      underwent secondary resection after first-line systemic
                      therapy. Rectum carcinoma had the best prognosis under
                      anti-EGFR-antibody treatment. Female patients had a worse
                      prognosis than male patients in late disease stage. Young
                      patients demonstrated poor response to systemic therapy, but
                      a high rate of conversion surgeries. Conversely, elderly
                      patients benefited from systemic therapy but underwent
                      surgery less frequently. Liver and lung metastases had a
                      worse prognosis than other metastases sites, whereas lung
                      metastases were more likely to be resected than liver
                      metastases in early disease stage.Patient age, sex, primary
                      tumor localization, and metastatic sites are prognostic
                      factors that could guide future treatment decisions for the
                      therapy of metastatic CRC.},
      keywords     = {Colorectal cancer (Other) / chemotherapy (Other) /
                      colorectal liver metastases (Other) / metastases (Other) /
                      secondary surgery (Other) / time-to-next-treatment (Other) /
                      tumor sidedness (Other)},
      cin          = {D240},
      ddc          = {610},
      cid          = {I:(DE-He78)D240-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38030166},
      doi          = {10.21873/anticanres.16761},
      url          = {https://inrepo02.dkfz.de/record/285693},
}